Back

Dual antithrombotic therapy with dabigatran vs triple therapy with warfarin after PCI in patients with atrial fibrillation and diabetes mellitus (a RE-DUAL PCI subgroup analysis)

28 August 2018 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Best Posters 6 - Best Posters in preventive cardiology Percutaneous Coronary Intervention (PCI) and Surgery ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Michael Maeng

Aarhus University Hospital, Aarhus (Denmark)

4 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Professor D. McGuire (Dallas, US)
Abstract Slides
Presentation thumbnail
Doctor B. Zhao (Hobart, AU)
Abstract Slides
Presentation thumbnail
Doctor D. Takagi (Kyouto, JP)
Abstract

Access the full session

Session thumbnail
Best Posters 6 - Best Posters in preventive cardiology

The Event

Event poster

ESC Congress 2018

28 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Meta-analysis of clinical trials comparing triple versus dual antithrombotic therapy on risk reduction of stent thrombosis after percutaneous coronary intervention in atrial fibrillation patients
27 August 2021
thumbnail
Webinar
Diabetes and ACS - enhancing post-discharge outcomes after primary PCI
26 May 2025
thumbnail
Webinar
How to manage elderly patients with atrial fibrillation and multiple comorbidities
12 November 2021
thumbnail
Congress Presentation
Ophthalmic complications in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin
25 April 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources